Citadel Advisors
HRTX icon

Citadel Advisors’s Heron Therapeutics HRTX Stock Holding History

Citadel Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.96K Hold
21,000
– – ﹤0.01% 13510
2026
Q1 		$16.8K Sell
21,000
-2,300
-10% -$2.67K ﹤0.01% 12701
2025
Q4 		$30.3K Sell
23,300
-36,300
-61% -$44.8K ﹤0.01% 12225
2025
Q3 		$75.1K Buy
+59,600
New +$94.5K ﹤0.01% 12009
2025
Q2 		– Sell
-47,700
Closed -$105K – 13600
2025
Q1 		$105K Buy
47,700
+37,700
+377% +$73.2K ﹤0.01% 11383
2024
Q4 		$15.3K Sell
10,000
-33,400
-77% -$54.1K ﹤0.01% 13359
2024
Q3 		$86.4K Buy
43,400
+15,200
+54% +$36.3K ﹤0.01% 11314
2024
Q2 		$98.7K Buy
28,200
+3,600
+15% +$11.1K ﹤0.01% 10933
2024
Q1 		$68.1K Sell
24,600
-4,400
-15% -$11.1K ﹤0.01% 11849
2023
Q4 		$49.3K Buy
29,000
+23,100
+392% +$25.4K ﹤0.01% 11791
2023
Q3 		$6.08K Sell
5,900
-10,900
-65% -$15.5K ﹤0.01% 13345
2023
Q2 		$19.5K Buy
16,800
+9,600
+133% +$17.1K ﹤0.01% 12742
2023
Q1 		$10.9K Sell
7,200
-3,800
-35% -$9.52K ﹤0.01% 13501
2022
Q4 		$27.5K Sell
11,000
-10,600
-49% -$34.1K ﹤0.01% 12836
2022
Q3 		$91K Sell
21,600
-1,600
-7% -$6.26K ﹤0.01% 11168
2022
Q2 		$65K Sell
23,200
-41,500
-64% -$167K ﹤0.01% 11761
2022
Q1 		$370K Sell
64,700
-40,800
-39% -$299K ﹤0.01% 10104
2021
Q4 		$963K Buy
105,500
+9,700
+10% +$99K ﹤0.01% 8064
2021
Q3 		$1.02M Sell
95,800
-700
-0.7% -$8.52K ﹤0.01% 8093
2021
Q2 		$1.5M Sell
96,500
-23,500
-20% -$374K ﹤0.01% 7320
2021
Q1 		$1.95M Buy
120,000
+84,200
+235% +$1.5M ﹤0.01% 6457
2020
Q4 		$758K Buy
35,800
+4,100
+13% +$71.3K ﹤0.01% 7369
2020
Q3 		$470K Sell
31,700
-77,700
-71% -$1.21M ﹤0.01% 7401
2020
Q2 		$1.61M Sell
109,400
-15,000
-12% -$246K ﹤0.01% 4943
2020
Q1 		$1.46M Buy
124,400
+70,500
+131% +$1.33M ﹤0.01% 4671
2019
Q4 		$1.27M Buy
53,900
+8,000
+17% +$177K ﹤0.01% 5173
2019
Q3 		$849K Buy
45,900
+6,100
+15% +$112K ﹤0.01% 5873
2019
Q2 		$740K Sell
39,800
-14,100
-26% -$282K ﹤0.01% 6199
2019
Q1 		$1.32M Buy
53,900
+18,000
+50% +$471K ﹤0.01% 5120
2018
Q4 		$931K Buy
35,900
+4,500
+14% +$124K ﹤0.01% 5428
2018
Q3 		$994K Sell
31,400
-11,200
-26% -$417K ﹤0.01% 5552
2018
Q2 		$1.66M Buy
42,600
+18,000
+73% +$573K ﹤0.01% 4392
2018
Q1 		$679K Buy
24,600
+10,000
+68% +$227K ﹤0.01% 5380
2017
Q4 		$264K Buy
+14,600
New +$238K ﹤0.01% 6664
2016
Q1 		– Sell
-7,900
Closed -$211K – 7272
2015
Q4 		$211K Sell
7,900
-23,100
-75% -$618K ﹤0.01% 5737
2015
Q3 		$756K Buy
31,000
+21,500
+226% +$717K ﹤0.01% 4199
2015
Q2 		$296K Sell
9,500
-11,700
-55% -$220K ﹤0.01% 5761
2015
Q1 		$308K Buy
21,200
+20,200
+2,020% +$228K ﹤0.01% 5608
2014
Q4 		$10K Buy
+1,000
New +$8.16K ﹤0.01% 8132

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Citadel Advisors's HRTX Position: Q2 2026 in Review

Citadel Advisors sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 759,269 shares — an estimated $609K sold.

Citadel Advisors first reported a position in HRTX in Q4 2014 and held it in 43 quarters. The position peaked at $68.5M in Q4 2018. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Citadel Advisors reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 759,269 Heron Therapeutics shares in Q2 2026, an estimated $609K.
  • Citadel Advisors first reported a position in Heron Therapeutics in Q4 2014 and held it in 43 quarters.
  • Citadel Advisors's Heron Therapeutics position peaked at $68.5M in Q4 2018.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.